Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 25;12(3):592.
doi: 10.3390/diagnostics12030592.

Relevance of ARID1A Mutations in Endometrial Carcinomas

Affiliations

Relevance of ARID1A Mutations in Endometrial Carcinomas

Antonio De Leo et al. Diagnostics (Basel). .

Abstract

Since the Cancer Genome Atlas (TCGA) project identified four distinct groups based on molecular alterations, mutation analyses have been integrated into the characterization of endometrial carcinomas (ECs). ARID1A seems to be the subunit more involved in the loss of function of the SWI/SNF complex in ECs. The aim of this study is to define the relevance of ARID1A alterations in a cohort of EC, studying the possible associations between DNA mutation (genomic level), RNA expression (transcriptomic level), and protein expression (proteomic level). A total of 50 endometrial carcinomas were characterized for ARID1A mutations (using targeted DNA next-generation sequencing-NGS), ARID1A gene expression (using RNAseq and qRT-PCR), and ARID1A protein expression (using immunohistochemistry-IHC). Moreover, we have investigated if ARID1A mutations may alter the protein structure, using the Protein Data Bank sequence. We found a good correlation between ARID1A mutations and protein immunostaining, even if we did not find statistically significant differences in the ARID1A expression levels. In conclusion, our data demonstrated that the molecular characterization of ARID1A should be associated with IHC analysis, mainly in those cases harboring "novel" ARID1A mutations or in those alterations with "uncertain" pathogenic significance.

Keywords: ARID1A; SWI/SNF complex; endometrial cancer; molecular classification; next-generation sequencing.

PubMed Disclaimer

Conflict of interest statement

D.d.B. has received personal fees (as speaker bureau) from Boehringer Ingelheim, and Eli Lilly, unrelated to the current work.

Figures

Figure 1
Figure 1
Immunohistochemical staining for ARID1A. (A) Preserved expression; (B) Loss of expression. Magnification: 200×.
Figure 2
Figure 2
ARID1A expression between wildtype and mutant patients by RNAseq. WT: ARID1A wildtype samples; MUT: ARID1A mutant samples.
Figure 3
Figure 3
ARID1A expression between wildtype and mutant patients by qRT-PCR. WT: ARID1A wildtype samples; MUT: ARID1A mutant samples.
Figure 4
Figure 4
Details of ARID1A Leu1100 (A), Asn1705 (B), Arg1833 (C), Arg1906 (D), and Leu2195 (E) and of the neighboring residues in the available structures. In each panel, the wildtype structure and the mutant calculated in silico have been reported on the left and on the right, respectively. ARID1A helices are in blue, while helices and strands from other SWI/SNF subunits are in light blue and in light yellow. The considered residue is in ball-and-stick representation while the residues in the vicinity are in sticks. The atoms are colored according to the atom type. The hydrogen bonds have been highlighted by using yellow dashed lines.

References

    1. Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., Gavin A., Visser O., Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer. 2018;103:356–387. doi: 10.1016/j.ejca.2018.07.005. - DOI - PubMed
    1. Allemani C., Matsuda T., Di Carlo V., Harewood R., Matz M., Niksic M., Bonaventure A., Valkov M., Johnson C.J., Esteve J., et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): Analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023–1075. doi: 10.1016/S0140-6736(17)33326-3. - DOI - PMC - PubMed
    1. Stelloo E., Nout R.A., Osse E.M., Jurgenliemk-Schulz I.J., Jobsen J.J., Lutgens L.C., van der Steen-Banasik E.M., Nijman H.W., Putter H., Bosse T., et al. Improved Risk Assessment by Integrating Molecular and Clinicopathological Factors in Early-stage Endometrial Cancer-Combined Analysis of the PORTEC Cohorts. Clin. Cancer Res. 2016;22:4215–4224. doi: 10.1158/1078-0432.CCR-15-2878. - DOI - PubMed
    1. Talhouk A., McConechy M.K., Leung S., Li-Chang H.H., Kwon J.S., Melnyk N., Yang W., Senz J., Boyd N., Karnezis A.N., et al. A clinically applicable molecular-based classification for endometrial cancers. Br. J. Cancer. 2015;113:299–310. doi: 10.1038/bjc.2015.190. - DOI - PMC - PubMed
    1. Talhouk A., McConechy M.K., Leung S., Yang W., Lum A., Senz J., Boyd N., Pike J., Anglesio M., Kwon J.S., et al. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. Cancer. 2017;123:802–813. doi: 10.1002/cncr.30496. - DOI - PubMed

LinkOut - more resources